Western Standard LLC’s Puma Biotechnology PBYI Stock Holding History

Western Standard LLC’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-141,614	Closed	-$334K	–	38
2022 Q1	$334K	Buy	+141,614	New	+$366K	0.32%	22

Other funds holding PBYI

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

ACM

Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Western Standard LLC's PBYI Position: Q2 2022 in Review

Western Standard LLC sold out of Puma Biotechnology (PBYI) in Q2 2022, closing a stake of 141,614 shares — an estimated $334K sold.

Western Standard LLC first reported a position in PBYI in Q1 2022 and held it in 1 quarter. The position peaked at $334K in Q1 2022. 88 funds tracked by Wall St. Rank hold PBYI as of Q2 2022.

Western Standard LLC reported no remaining Puma Biotechnology position as of Q2 2022 after selling out during the quarter.
Western Standard LLC sold 141,614 Puma Biotechnology shares in Q2 2022, an estimated $334K.
Western Standard LLC first reported a position in Puma Biotechnology in Q1 2022 and held it in 1 quarter.
Western Standard LLC's Puma Biotechnology position peaked at $334K in Q1 2022.
88 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2022.

Based on Western Standard LLC's 13F filing for Q2 2022, filed 15 Aug 2022.